Oncology
Clinical research is centered on advanced and metastatic solid tumors, with attention to tumors driven by RET alterations and treatment settings where targeted therapy is relevant.
- Solid tumor oncology
- Metastatic cancer
- RET-positive tumors
The sponsor’s trial activity in this area reflects interest in precision oncology and the clinical management of patients with advanced malignant disease.
Targeted cancer therapy
Research activity includes the therapeutic use of pralsetinib in RET inhibitor development, supporting investigation of molecularly guided treatment strategies in oncology.
- RET-targeted treatment
- Kinase inhibition
- Molecular oncology
The focus remains on therapeutic areas where oncogenic signaling is a central driver of disease progression.
Drug interaction and clinical pharmacology
The sponsor also supports research in drug-drug interaction assessment, with attention to how oncology therapies may affect the handling of other medicinal products.
- CYP3A pathways
- CYP2C8 pathways
- CYP2C9 pathways
This area includes interest in pharmacokinetic behavior and the interaction profile of small-molecule therapies used in cancer care.
Hormone-related interaction research
Clinical interest extends to the interaction of oncology treatment with estradiol and norethisterone acetate, reflecting attention to concomitant hormonal agents used in clinical practice.
- Hormone exposure
- Concomitant medication effects
- Endocrine-related pharmacology
These studies support evaluation of how cancer therapies may be used alongside hormonal medications in patients with complex treatment needs.
